Get the Oncomine Comprehensive Myeloid Panel Test for only $1112 USD in USA. Advanced NGS testing for leukemia detection
Get comprehensive genetic testing for Leber Congenital Amaurosis with our Nx Gen Sequencing test for only $716 USD. Early diagnosis helps manage inherited retinal disorders. Available across major US cities including New York Nx Gen Sequencing Leber Congenital Amaurosis Test Original price was: $796.Current price is: $716.
Get accurate Pan Fungal Detection PCR Test for $162 USD in USA. Advanced molecular testing detects fungal infections in blood Pan Fungal Detection PCR Test Original price was: $250.Current price is: $162.
Sale!

Oncomine Comprehensive Myeloid Panel Test

Original price was: $1,236.Current price is: $1,112.

-10%

The Oncomine Comprehensive Myeloid Panel Test is a cutting-edge next-generation sequencing (NGS) analysis designed to detect genetic mutations associated with myeloid malignancies. This comprehensive panel evaluates over 70 key genes including FLT3, NPM1, IDH1, IDH2, JAK2, and CALR, providing crucial insights for leukemia diagnosis, prognosis, and treatment selection. The test is particularly valuable for patients with suspected or confirmed myeloid disorders, offering detailed genetic profiling that guides targeted therapy decisions. With a discounted price of $1112 USD, this advanced molecular diagnostic tool helps hematologists and oncologists develop personalized treatment strategies based on specific genetic alterations. The test requires a simple blood or bone marrow sample and delivers results within the same month, making it an essential component of modern hematologic cancer care.

Trusted Testing. Expert Care. Guaranteed Privacy.

  • Accredited and Trusted
  • Expert Scientists, Advanced Technology
  • Data Privacy Guaranteed
Guaranteed Safe Checkout

Oncomine Comprehensive Myeloid Panel Test

Comprehensive Genetic Analysis for Myeloid Malignancies

The Oncomine Comprehensive Myeloid Panel Test represents a revolutionary advancement in molecular diagnostics for hematologic cancers. This sophisticated next-generation sequencing (NGS) panel provides comprehensive genetic profiling specifically designed for myeloid malignancies, offering unprecedented insights into the genetic landscape of leukemia and related disorders. By analyzing over 70 critical genes associated with myeloid cancers, this test delivers essential information that directly impacts diagnosis, prognosis, and treatment selection.

What Does the Test Measure?

The Oncomine Comprehensive Myeloid Panel Test employs cutting-edge NGS technology to detect mutations, fusions, and genetic alterations across a comprehensive spectrum of genes crucial for myeloid cancer development and progression. The panel covers:

  • Key Mutation Genes: ABL1, ASXL1, BCOR, BAALC, BRAF, CALR, CEBPA, CBL, CSF3R, DNMT3A, EZH2, ETV6, FLT3, GATA2, HRAS, IDH1, IDH2, IKZF1, JAK2, KIT, KRAS, MPL, MYD88, MYC, NPM1, NRAS, NF1, PTPN11, PHF6, PRPF8, RB1, RUNX1, SETBP1, SF3B1, SRSF2, SH2B3, SMC1A, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2
  • Fusion Gene Analysis: ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, ETV6, FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A, MLLT3, MLLT10, MECOM, MET, MYBL1, MYH11, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM15, RUNX1, TCF3, TFE3

Who Should Consider This Test?

This comprehensive myeloid panel is recommended for individuals presenting with:

  • Suspected or confirmed acute myeloid leukemia (AML)
  • Myelodysplastic syndromes (MDS)
  • Myeloproliferative neoplasms (MPN)
  • Unexplained cytopenias or abnormal blood counts
  • Family history of hematologic malignancies
  • Patients requiring treatment response monitoring
  • Individuals with recurrent or treatment-resistant myeloid disorders

Clinical Benefits and Applications

The Oncomine Comprehensive Myeloid Panel Test offers numerous clinical advantages:

  • Precise Diagnosis: Identifies specific genetic mutations that define different subtypes of myeloid malignancies
  • Prognostic Stratification: Provides critical information about disease aggressiveness and likely clinical course
  • Treatment Guidance: Identifies targetable mutations for personalized therapy selection
  • Minimal Residual Disease Monitoring: Enables tracking of treatment response and early detection of relapse
  • Comprehensive Coverage: Single test evaluates multiple genetic alterations, reducing the need for sequential testing

Understanding Your Test Results

Your comprehensive myeloid panel results will provide detailed information about detected genetic alterations:

  • Positive Results: Indicate the presence of specific mutations or fusions that may guide treatment decisions
  • Negative Results: Suggest absence of the tested genetic alterations in the analyzed sample
  • Variant of Uncertain Significance (VUS): Genetic changes whose clinical significance is not yet established
  • Interpretation: Results should be discussed with your hematologist or oncologist in the context of your complete clinical picture

Test Pricing and Availability

Test Name Discount Price Regular Price
Oncomine Comprehensive Myeloid Panel Test $1112 USD $1236 USD

Sample Requirements and Processing

Sample Type: 3 mL (2 mL min.) whole Blood OR Bone Marrow in 1 Lavender top (EDTA) tube. Ship refrigerated. DO NOT FREEZE.

Turnaround Time: Sample by 1st / 16th of every month; Report 15th / 30th of Same month

Pre-test Instructions: Duly filled NGS Test Requisition Form (Form 40) is mandatory.

Nationwide Availability

We have branches across all major cities in the USA, including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our comprehensive network ensures convenient access to advanced genetic testing services nationwide.

Book Your Test Today

Take the first step toward comprehensive myeloid cancer diagnosis and personalized treatment planning. Our expert team is ready to assist you with scheduling and answer any questions about the Oncomine Comprehensive Myeloid Panel Test.

Call or WhatsApp: +1(267) 388-9828

Schedule your appointment today and benefit from cutting-edge genetic analysis that can transform your approach to myeloid malignancy management.

SKU: 1803 Category:

Related products